Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. (formerly Stem Cell Assurance, Inc.) on August 15, 2011. The report details a corporate name change and the associated change in the company's stock trading symbol.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Name Change: Effective August 15, 2011, the company changed its name from Stem Cell Assurance, Inc. to BioRestorative Therapies, Inc.
- Method: The change was effected through a merger of a wholly-owned subsidiary, BioRestorative Therapies, Inc., into the parent company. The filing states this did not alter the Articles of Incorporation or corporate structure beyond the name change.
- Trading Symbol: The stock symbol will change from "SCLZ" to "BRTX" thirty days following the FINRA announcement.
- Website: The company's new website address is www.biorestorative.com.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors related to operations. It notes that the press release furnished as an exhibit is not incorporated by reference into registration statements and does not constitute an admission of materiality for investment decisions.
Investor Verification Checklist
- Verify the effective date of the stock symbol change from SCLZ to BRTX with FINRA or the exchange.
- Confirm the new corporate website (www.biorestorative.com) is active and reflects the rebranding.
- Review the Articles of Merger (Exhibit 3(i)(a)) to confirm no hidden structural changes occurred.
- Check subsequent filings for financial data, as this 8-K contains none.